Mankind Pharma Ltd Quarterly Results Q4FY26 stock analysis

Home » Core Investor Group » Mankind Pharma Ltd Q4FY26 Result Update

Sector Outlook: Positive

Broad-based domestic recovery and specialty traction drive strong earnings beat Near Term Profitability

The company posted a revenue increase of 11.8% YoY / down 3.5% QoQ to Rs. 34,429 mn, above our expectations of Rs. 34,060 mn, driven by strong growth in the domestic business, continued traction in chronic therapies, and robust performance from the BSV specialty portfolio. Domestic business delivered healthy broad-based growth across cardiac, anti-diabetic, gynecology, gastro, vitamins, and IVF therapies, supported by improving execution, higher prescription share, and strong doctor penetration. Chronic mix continued to improve with chronic contribution rising 120 bps YoY to ~40% during the quarter. Export business remained impacted by geopolitical headwinds during the quarter; however, full-year international revenue still grew 35% YoY, supported by expansion in semi-regulated markets and BSV integration benefits. EBITDA increased 36.1% YoY / up 1.1% QoQ to Rs. 9,299 mn, while EBITDA margin stood at 27.0% (up 482bps YoY) in Q4FY26, supported by gross margin improvement, operating leverage benefits, and normalization of launch/relaunch expenses incurred in the base quarter. In Q4FY26, PAT stood at Rs. 5,594 mn (up 30.4% YoY / up 35.2% QoQ) in Q4FY26, above our expectations of Rs. 5,250 crores. PAT margin rise 16.2% versus 11.8% in the previous quarter. Management guided for stronger FY27 performance with expectations of double-digit revenue growth, continued chronic therapy outperformance and improving acute recovery.

Valuation and Outlook

Mankind Pharma’s strong Q4FY26 performance reflects improving execution across domestic formulations, recovery in acute therapies, and sustained momentum in chronic and specialty businesses. Healthy traction in cardiac, anti-diabetic, gynecology, IVF, and OTC portfolios along with better product mix supported margin expansion, while operating leverage and lower finance costs drove strong PAT growth. BSV integration continues to strengthen the specialty portfolio with improving prescription coverage, higher doctor reach, and expanding IVF penetration. Going ahead, management remains optimistic on FY27 with expectations of double-digit revenue growth led by recovery in the acute segment, continued outperformance in chronic therapies, increasing contribution from specialty and GLP-1-related products, and improving international business traction. EBITDA margin guidance of 25.5%-26.5%, ongoing debt reduction, enhanced R&D focus, and the upcoming biotech facility provide strong medium-term growth visibility despite near-term geopolitical and raw material cost uncertainties. This integrated growth strategy, supported by substantial brand equity and balance sheet strength, provides high visibility of earnings expansion and positions the company as a long-term compounding opportunity in the Indian healthcare sector. Thus, we expect Mankind Pharma to generate stable revenues over the long term and is trading at a PE of 40.2x/34.1x on FY27e/28e EPS estimates. We value Mankind Pharma at 46x FY27e EPS and have revised the target price to Rs 2,878 (up 15%).

Key concall Highlights

Domestic Business Outlook:

Domestic business recovery remains firmly on track, with management guiding for sustained double-digit growth in FY27 driven by normalization in acute therapies, continued strength in chronic segments, and robust momentum across specialty businesses. Improving contribution from cardiac, anti-diabetic, respiratory, IVF, and women healthcare therapies continues to enhance the overall business mix, while stronger prescription trends, better field productivity, and deeper doctor penetration are expected to support consistent outperformance versus IPM. Additionally, management remains focused on driving profitable growth across GLP-1 and OTC portfolios, supported by favorable product mix, operating leverage benefits, and disciplined cost management initiatives.

Acute profile:

Management indicated that the acute portfolio recovery is steadily gaining momentum following a subdued FY26, with sequential improvement visible from Q2FY26 across key therapies. FY27 acute growth is expected to broadly align with industry growth, supported by stabilization in field execution, normalization of operations, improving prescription traction, and recovery across gastro, gynecology, vitamins, anti-infectives, and other core acute segments.

India Consumer Healthcare Business:

The India Consumer Healthcare business to witnessed healthy double-digit growth in FY27, driven by strengthening core brands, improving execution, and continued traction across modern trade and e-commerce channels. The company remains focused on scaling existing brands through extensions rather than aggressive new product launches, while improving channel mix, operational efficiencies, and digital penetration are expected to support margin improvement and sustainable long-term growth.

International Business Outlook:

The international business remains optimistic despite near-term geopolitical disruptions impacting select markets during Q4FY26. The company expects high-teen growth over the medium term, driven by expanding women healthcare, fertility, and IVF portfolios, deeper penetration in GTM markets such as Philippines, Malaysia, and Africa, and new launches in semi-regulated markets. Additionally, EU-GMP approvals for the Udaipur and Ambernath facilities, along with improving BSV integration and leadership stabilization in key regions, are expected to support stronger execution and sustained international growth going ahead.

R&D Pipeline:

The company continues to strengthen its R&D pipeline with increasing focus on specialty, biologics, and differentiated products to drive long-term growth. R&D spend increased to ~2.8% of sales in FY26 in line with strategic priorities, while the upcoming biotech facility in Vadodara is expected to enhance capabilities in complex product development.

BSV Portfolio:

The BSV portfolio, highlighting strong traction across women healthcare, fertility, IVF, and specialty therapies. Key brands such as Anti-D, Foligraf, and HMG continued to witness robust growth, supported by increasing doctor coverage, deeper penetration across IVF centers and state hospitals, and rising awareness initiatives.

Capex:

The company has outlined an elevated Capex trajectory over the medium term, primarily driven by investments in the upcoming Vadodara biotech facility aimed at strengthening biologics, specialty, and complex product capabilities. The company’s FY26 Capex stood at Rs. 737 crores (~5.2% of revenue), while FY27 Capex guidance has been increased to 6%-7% of revenue to support biotech manufacturing expansion, R&D infrastructure, and future specialty pipeline growth.